Melanoma is one of the most treatable cancers when caught early, with a five-year survival rate of 97.6% for tumors that haven’t spread beyond the skin. Even across all stages combined, about 90.5% of people diagnosed with melanoma survive at least five years. The picture changes significantly once the cancer reaches lymph nodes or distant organs, but advances in treatment over the past decade have improved outcomes at every stage.
Why Stage at Diagnosis Matters Most
The single biggest factor in how treatable your melanoma is comes down to how deep the tumor has grown and whether it has spread. Doctors measure depth in millimeters, called Breslow thickness, and this number strongly predicts survival. Tumors thinner than 0.75 mm carry roughly a 95% survival rate. Between 0.75 and 1.49 mm, that drops to about 85%. Tumors between 1.5 and 3.99 mm see survival around 66%, and anything 4 mm or deeper falls to about 46%.
The formal staging system groups these numbers into broader categories. Stage 0 (melanoma confined to the outermost layer of skin) has a 100% five-year survival rate. Stages I and II, where the cancer is still localized, sit at 97.6%. Stage III, meaning cancer has reached nearby lymph nodes, drops to 60.3%. Stage IV, with distant spread to organs like the lungs, liver, or brain, has a five-year survival rate of 16.2%. These numbers reflect averages across many patients, and individual outcomes vary based on tumor biology, location, and treatment response.
Surgery for Early-Stage Melanoma
For melanoma that hasn’t spread, surgery is the primary treatment and is often the only treatment needed. The procedure involves removing the tumor along with a margin of healthy skin around it. For melanoma in situ (stage 0), guidelines call for a margin of 5 mm to 1 cm. Thicker tumors require wider margins. Melanomas on the head and neck can be trickier because surgeons need to balance removing enough tissue with preserving function and appearance. A 5 mm margin for certain types of melanoma in situ on the head and neck often results in incomplete removal, so surgeons may need to check the edges under a microscope during the procedure.
For tumors of a certain thickness, doctors typically recommend a sentinel lymph node biopsy at the same time as surgery. This involves identifying and removing the first lymph node where the cancer would drain, then checking it for cancer cells. The status of that node is one of the strongest predictors of long-term outcome. If the sentinel node is negative, the risk of the cancer later showing up in lymph nodes is less than 5%.
Treatment After Surgery for Stage III
When melanoma has reached nearby lymph nodes, surgery alone carries a meaningful risk of recurrence. Immunotherapy given after surgery (called adjuvant therapy) reduces that risk. In major clinical trials, patients who received immunotherapy after having stage III melanoma surgically removed had 12-month recurrence-free survival rates between 70% and 75%, compared to lower rates for those who didn’t receive it. This doesn’t guarantee the cancer won’t return, but it shifts the odds meaningfully in your favor.
A newer approach flips the timeline: giving immunotherapy before surgery. The idea is to shrink the tumor and prime the immune system while the cancer is still present in the body. A large meta-analysis of 43 studies involving over 2,800 patients found that about 33% of people who received pre-surgery immunotherapy had a complete pathologic response, meaning no viable cancer cells were found in the tissue removed during surgery. The overall survival rate across these studies was 81%. This approach is gaining traction, though the specific drugs and dosing schedules are still being refined.
Advanced Melanoma Treatment
Stage IV melanoma was once considered nearly untreatable. Before 2011, median survival after diagnosis of metastatic melanoma was measured in months, and effective drug options barely existed. That has changed dramatically.
Two main categories of treatment now exist for advanced melanoma. The first is immunotherapy, which works by releasing the brakes on your immune system so it can recognize and attack cancer cells. These drugs have produced durable, long-lasting responses in a portion of patients, with some remaining cancer-free for years after treatment.
The second is targeted therapy, used for the roughly 40-50% of melanomas that carry a specific genetic mutation called BRAF. Drugs that block this mutation, combined with drugs that block a related pathway called MEK, can shrink tumors rapidly. In real-world data from 435 patients, the median overall survival on this combination was about 12 months. Patients whose health and tumor characteristics most closely matched clinical trial criteria did better, with a median survival of nearly 18 months and a two-year survival rate of 39%. These drugs tend to work quickly but resistance often develops over time, which is why immunotherapy is frequently preferred as a first-line treatment when possible.
Recurrence Patterns and Monitoring
Understanding when melanoma is most likely to come back helps explain why follow-up schedules are structured the way they are. A Danish study tracking over 25,700 melanoma patients found that recurrences are front-loaded: about 29% happen within the first year after treatment, and just over half occur within two years. By five years, 82% of all recurrences have already appeared. The remaining 18% trickle in over the following years, with nearly all recurrences (99.4%) occurring within ten years.
This means the first two to three years after treatment are the highest-risk window, and monitoring is most intensive during that period. It also means that passing the five-year mark without recurrence is a strong positive signal, though it doesn’t eliminate risk entirely. Late recurrences beyond five years do happen with melanoma more than with many other cancers, which is why long-term skin checks remain important even years after treatment.
What Makes Melanoma Different
Melanoma’s treatability spans an unusually wide range compared to other cancers. A thin melanoma caught early is one of the most curable cancers that exists. A thick melanoma that has spread to distant organs remains one of the more difficult to treat, despite real progress. The gap between these two scenarios is enormous, which is why dermatologists emphasize regular skin exams and awareness of changing moles.
The practical takeaway is that depth and spread at the time of diagnosis determine your treatment path more than almost anything else. A melanoma caught at 0.5 mm deep typically requires a single outpatient surgery and regular follow-up. A melanoma caught at 4 mm or deeper may involve lymph node surgery, months of immunotherapy, imaging scans, and years of close surveillance. Both are treatable, but the complexity, duration, and uncertainty of treatment increase sharply with stage.